Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer

被引：0
|
作者：
Jeffrey Franks
Nicole E. Caston
Ahmed Elkhanany
Travis Gerke
Andres Azuero
Gabrielle B. Rocque
机构：
[1] University of Alabama at Birmingham,Department of Medicine, Division of Hematology and Oncology
[2] O’Neal Comprehensive Cancer Center,School of Nursing
[3] The Prostate Cancer Clinical Trials Consortium,undefined
[4] University of Alabama at Birmingham,undefined
来源：
Breast Cancer Research and Treatment | 2023年 / 197卷
关键词：
Cyclin-dependent kinase 4/6 inhibitors; Visualization; Duration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：673 / 681
页数：8
相关论文
共 50 条
  • [41] Androgen Receptor in Hormone Receptor-Positive Breast Cancer
    Khan, Ashfia Fatima
    Karami, Samaneh
    Peidl, Anthony S.
    Waiters, Kacie D.
    Babajide, Mariam Funmi
    Bawa-Khalfe, Tasneem
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [42] Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer
    Cosin, Marc
    Tian, Tian
    Oliveros, Winona
    Kharenko, Olesya A.
    van der Horst, Edward H.
    Patel, Reena G.
    Calosing, Cyrus
    Campeau, Eric
    Jahagirdar, Ravi
    Lakhotia, Sanjay
    Mele, Marta
    Palafox, Marta
    Arribas, Joaquin
    Oliveira, Mafalda
    Saura, Cristina
    Serra, Violeta
    Peiro, Sandra
    CANCER RESEARCH, 2020, 80 (16)
  • [43] Palbociclib for hormone receptor-positive breast cancer
    Harding, Emilia
    LANCET ONCOLOGY, 2015, 16 (07): : E318 - E318
  • [44] Disparities in Hormone Receptor-Positive Breast Cancer
    Esther R. Ogayo
    Elizabeth A. Mittendorf
    Olga Kantor
    Current Breast Cancer Reports, 2024, 16 : 106 - 115
  • [45] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
  • [46] Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis
    Ergun, Yakup
    Dogan, Mutlu
    Ucar, Gokhan
    Karacin, Pinar
    Karacin, Cengiz
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (17) : 1901 - 1909
  • [47] Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Spring, Laura
    Niemierko, Andrzej
    Juric, Dejan
    Zangardi, Mark
    Abraham, Elizabeth
    Dias-Santagata, Dora
    Ellisen, Leif W.
    Isakoff, Steven J.
    Iafrate, A. John
    Moy, Beverly
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer
    Zheng, Yang
    Zhang, Zeyuan
    Li, Dan
    Huang, Rong
    Ning, Shipeng
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (05):
  • [49] Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All
    Li, Jianbin
    CANCERS, 2025, 17 (04)
  • [50] CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care
    Hui, Rina
    de Boer, Richard
    Lim, Elgene
    Yeo, Belinda
    Lynch, Jodi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 3 - 14
12345